Skip to main content

Lazertinib Shows Promising Antitumor Activity in Patients With EGFR+ NSCLC

*December 2019*

With the inevitability of resistance to first- and second-generation EGFR tyrosine kinase inhibitors (TKIs) in patients with EGFR-mutant non–small cell lung cancer (NSCLC), novel options like lazertinib (YH25448), an irreversible, third-generation, mutant-selective, EGFR TKI are being explored. Lazertinib has shown promise for the treatment of this patient population, according to a phase I/II dose-escalation study (NCT03046992) published in The Lancet Oncology.

Read more.